DNY59
BioNTech (NASDAQ:BNTX) has entered into a patent assignment and license agreement to acquire one of CellmAbs’ pre-clinical antibody candidates and additional ADC technology, a deal that could be worth around a billion dollars, according to CellmAbs.
Under the deal, CellmAbs will receive upfront and near-term payments and could be eligible to receive “several hundred million US Dollars” in milestone payments, plus tiered royalty payments, according to a CellmAbs statement released earlier this week.
Based in Portugal, CellmAbs was spun out of NOVA University of Lisbon in 2019. CellmAbs said the BioNTech deal could mark “Portugal’s first billion-dollar transaction in the life sciences sector.”
Financial details were not disclosed.
BioNTech released its preliminary 2023 financial results, 2024 revenue forecast and a business update at the annual JP Morgan Healthcare Conference earlier this week.
